AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28763316 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (5 mg/kg) coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Number of subjects: 53
Study 28763316 — intervention group
Group type: COMPARATOR
Intervention: Normal saline coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Number of subjects: 53
Study 26243641 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with public commitment and reminder
Number of subjects: 408
Study 26243641 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with infrastructure promotion and reminder
Number of subjects: 408
Study 26243641 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (education only)
Number of subjects: 408
Study 23468553 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lipid-based nutrient supplements (LNS) during lactation
Number of subjects: 1619
Study 23468553 — intervention group
Group type: COMPARATOR
Intervention: No LNS (Control)
Number of subjects: 1619
Study 21699777 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with fast-track multimodal management
Number of subjects: 93
Study 21699777 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery with standard care
Number of subjects: 93
Study 21699777 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with fast-track care
Number of subjects: 93
Study 21699777 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with standard care
Number of subjects: 93
Study 18057307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (n = 25, 12 males)
Number of subjects: 50
Study 18057307 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (n = 25, 13 males)
Number of subjects: 50
Study 16490808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 20 mg for 7 days with CyA 100 mg coadministered on day 7
Number of subjects: 0
Study 16490808 — intervention group
Group type: COMPARATOR
Intervention: CyA 100 mg alone
Number of subjects: 0
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access follow-up
Number of subjects: 180
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial experience
Number of subjects: 180
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care guideline awareness
Number of subjects: 180
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Management problems
Number of subjects: 180
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Encounter Form usage
Number of subjects: 180
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for written guidelines
Number of subjects: 180
Study 11818350 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of GI nurse practitioner
Number of subjects: 180
Study 10564333 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine (8 mg)
Number of subjects: 60
Study 10564333 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 60
Study 10564333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 60
Study 8563277 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system for the management of mechanical ventilation in ARDS patients
Number of subjects: 0
Study 2162875 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-Li CT
Number of subjects: 22
Study 2162875 — intervention group
Group type: COMPARATOR
Intervention: Resting blood pressure
Number of subjects: 22
Study 2162875 — intervention group
Group type: COMPARATOR
Intervention: Standing DBP
Number of subjects: 22
Study 913121 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg flurbiprofen daily
Number of subjects: 24
Study 913121 — intervention group
Group type: COMPARATOR
Intervention: 150 mg indomethacin daily
Number of subjects: 24
Study 7225165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg tid for 4 weeks
Number of subjects: 30
Study 7225165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg tid for 9 weeks
Number of subjects: 30
Study 7225165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg tid for 9 weeks in 10 subjects with lipoprotein cholesterol fractionation
Number of subjects: 30
Study 30778571 — intervention group
Group type: EXPERIMENTAL
Intervention: EOD1 (Essential oil blends and Vitamin D3; 50 μg 25‐OH‐D3/kg diet, 15 mg CRINA Poultry/kg diet)
Number of subjects: 800
Study 30778571 — intervention group
Group type: EXPERIMENTAL
Intervention: EOD2 (Essential oil blends and Vitamin D3; 69 μg 25‐OH‐D3/kg diet, 30 mg CRINA Poultry/kg diet)
Number of subjects: 800
Study 30778571 — intervention group
Group type: EXPERIMENTAL
Intervention: EOD3 (Essential oil blends and Vitamin D3; 138 μg 25‐OH‐D3/kg diet, 50 mg CRINA Poultry/kg diet)
Number of subjects: 800
Study 30778571 — intervention group
Group type: EXPERIMENTAL
Intervention: EOD2 and EOD3
Number of subjects: 800
Study 30778571 — intervention group
Group type: EXPERIMENTAL
Intervention: EOD1, EOD2, and EOD3
Number of subjects: 800
Study 30778571 — intervention group
Group type: COMPARATOR
Intervention: CON (Control group, unvaccinated birds fed basal diet)
Number of subjects: 800
Study 30778571 — intervention group
Group type: COMPARATOR
Intervention: CCO (CON + coccidian oocysts vaccinated birds)
Number of subjects: 800
Study 29851824 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of rocuronium intravenously (group L)
Number of subjects: 98
Study 29851824 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg/kg of rocuronium (group C)
Number of subjects: 98
Study 27439370 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 0.625 μg
Number of subjects: 70
Study 27439370 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 2.5 μg
Number of subjects: 70
Study 27439370 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 5 μg
Number of subjects: 70
Study 27439370 — intervention group
Group type: EXPERIMENTAL
Intervention: Abediterol 10 μg
Number of subjects: 70
Study 27439370 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 150 μg
Number of subjects: 70
Study 27439370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24128379 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated/co-located (ICL) healthcare
Number of subjects: 296
Study 24128379 — intervention group
Group type: COMPARATOR
Intervention: Non-co-located (NCL) healthcare
Number of subjects: 296
Study 24128379 — intervention group
Group type: COMPARATOR
Intervention: Harm reduction/outreach (HRO) settings
Number of subjects: 296
Study 24128379 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid substitution therapy (OST)
Number of subjects: 296
Study 22292061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by clinical pharmacists including answering questions of physicians and nurses, giving advice on treating patients, checking prescriptions and patient counseling at discharge.
Number of subjects: 160
Study 22292061 — intervention group
Group type: COMPARATOR
Intervention: Control group without clinical pharmacist interventions.
Number of subjects: 160
Study 22292061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by clinical pharmacists.
Number of subjects: 160
Study 21054896 — intervention group
Group type: COMPARATOR
Intervention: Amniotomy (group 1)
Number of subjects: 213
Study 21054896 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (group 2)
Number of subjects: 213
Study 21054896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both amniotomy and oxytocin (group 3)
Number of subjects: 213
Study 21054896 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 213
Study 17516484 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (ENT), 3 to 5 times daily
Number of subjects: 161
Study 17516484 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline (CBG), titrated to a maximum of 6 mg/d
Number of subjects: 161
Study 17516484 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (ENT)
Number of subjects: 161
Study 17516484 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline (CBG)
Number of subjects: 161
Study 16330964 — intervention group
Group type: EXPERIMENTAL
Intervention: gentian violet
Number of subjects: 146
Study 16330964 — intervention group
Group type: COMPARATOR
Intervention: nonadherent absorbent dressing
Number of subjects: 146
Study 12390384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg intravenously twice daily followed by oral ranitidine 150 mg twice daily for 5 years
Number of subjects: 740
Study 12390384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine in non-transfused patients (n = 202)
Number of subjects: 740
Study 12390384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine in non-transfused patients without postoperative infectious complications (n = 170)
Number of subjects: 740
Study 12390384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine in curatively resected patients (including Dukes' stage, age, gender, tumour location, blood transfusion, postoperative infectious complications)
Number of subjects: 740
Study 12390384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 10090428 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg once daily for 10 days
Number of subjects: 342
Study 10090428 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily for 10 days
Number of subjects: 342
Study 10090428 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 342
Study 10090428 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 342
Study 7751483 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intervention combining education with behavior skills training
Number of subjects: 246
Study 7751483 — intervention group
Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 246
Study 2281760 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 47
Study 2281760 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 47
Study 373395 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure at 95 dB A
Number of subjects: 18
Study 373395 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure at 75 and 85 dB A
Number of subjects: 18
Study 373395 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-noise stimulation
Number of subjects: 18
Study 31153360 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 0 mcg/kg (group 1)
Number of subjects: 180
Study 31153360 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 0.3 mcg/kg (group 2)
Number of subjects: 180
Study 31153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 mcg/kg (group 3)
Number of subjects: 180
Study 31153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.9 mcg/kg (group 4)
Number of subjects: 180
Study 28872503 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 30
Study 28872503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (manual superficial sliding movements)
Number of subjects: 30
Study 25595113 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm vein (AV) bypass
Number of subjects: 64
Study 25595113 — intervention group
Group type: COMPARATOR
Intervention: Contralateral greater saphenous vein (CGSV) bypass
Number of subjects: 64
Study 24448227 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg daily for 24 months
Number of subjects: 71
Study 24448227 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg daily for 24 months
Number of subjects: 71
Study 21917822 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK8007
Number of subjects: 0
Study 21917822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19733003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (RPN)
Number of subjects: 423
Study 17263650 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 500 mg/100 mg
Number of subjects: 216
Study 17263650 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 500 mg/200 mg
Number of subjects: 216
Study 17263650 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 750 mg/200 mg
Number of subjects: 216
Study 15024665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (ice bag on ankle dorsiflexors)
Number of subjects: 6
Study 15024665 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 6
Study 12473477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g)
Number of subjects: 330
Study 12473477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (1 g)
Number of subjects: 330
Study 12473477 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 mL sterile water)
Number of subjects: 330
Study 9666830 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 times weekly narrow-band TL-01 UVB phototherapy
Number of subjects: 21
Study 9666830 — intervention group
Group type: COMPARATOR
Intervention: 3 times weekly narrow-band TL-01 UVB phototherapy
Number of subjects: 21
Study 7648653 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg TID)
Number of subjects: 946
Study 7648653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946
Study 2667654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cytotoxic chemotherapy (76 patients)
Number of subjects: 399
Study 2667654 — intervention group
Group type: COMPARATOR
Intervention: No systemic adjuvant treatment (93 patients)
Number of subjects: 399
Study 2667654 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (oral cyclophosphamide and intravenous methotrexate and 5‐fluorouracil) for 12 cycles over one year
Number of subjects: 399
Study 908220 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 400 μg
Number of subjects: 20
Study 908220 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 200 μg
Number of subjects: 20
Study 908220 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 100 μg
Number of subjects: 20
Study 908220 — intervention group
Group type: EXPERIMENTAL
Intervention: isoproterenol 150 μg
Number of subjects: 20
Study 908220 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 908220 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug regimens
Number of subjects: 20
Study 31549290 — intervention group
Group type: EXPERIMENTAL
Intervention: First pass radionuclide angiography (FPRNA)
Number of subjects: 46
Study 29728338 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with Magnesium (Mg)
Number of subjects: 16
Study 29728338 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with maltose
Number of subjects: 16
Study 28210090 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block treatment (experimental group, n = 90)
Number of subjects: 120
Study 28210090 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfasalazine treatment (control group, n = 30)
Number of subjects: 120
Study 26383493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio diet (20% of total energy)
Number of subjects: 30
Study 26383493 — intervention group
Group type: COMPARATOR
Intervention: Control diet (without pistachios)
Number of subjects: 30
Study 23163421 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse TMS delivered at 120% distance-adjusted individual motor threshold over rFEF
Number of subjects: 21
Study 23163421 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse TMS delivered at 120% distance-adjusted individual motor threshold over rIFG
Number of subjects: 21
Study 23163421 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pulse TMS delivered at 120% distance-adjusted individual motor threshold over rPPC
Number of subjects: 21
Study 21994957 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 16
Study 21994957 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 16
Study 21994957 — intervention group
Group type: COMPARATOR
Intervention: XLH reference population
Number of subjects: 16
Study 18505226 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (3M)
Number of subjects: 32
Study 18505226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Kuraray)
Number of subjects: 32
Study 18505226 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (Dentsply)
Number of subjects: 32
Study 18505226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with 37% phosphoric acid gel
Number of subjects: 32
Study 18505226 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III with 37% phosphoric acid gel
Number of subjects: 32
Study 16455632 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PET scan with 3.3-4 MBq/kg of 18F-fluorocholine
Number of subjects: 26
Study 16455632 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PET scan with 3.3-4 MBq/kg of 18F-fluorocholine
Number of subjects: 26
Study 15287163 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 0
Study 15287163 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic regression model
Number of subjects: 0
Study 15287163 — intervention group
Group type: EXPERIMENTAL
Intervention: Different regression models
Number of subjects: 0
Study 11142927 — intervention group
Group type: EXPERIMENTAL
Intervention: Formica rufa D6 (1 ml) + autologous blood (0.5 ml)
Number of subjects: 104
Study 11142927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.5 ml NaCl intramuscular)
Number of subjects: 104
Study 8678737 — intervention group
Group type: COMPARATOR
Intervention: Classical transplantation (gr. I, n = 40)
Number of subjects: 78
Study 8678737 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical transplantation (gr. II, n = 41)
Number of subjects: 78
Study 8678737 — intervention group
Group type: COMPARATOR
Intervention: Classical transplantation (gr. I)
Number of subjects: 78
Study 8678737 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical transplantation (gr. II)
Number of subjects: 78
Study 8678737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 1510000 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg body weight in 10 minutes)
Number of subjects: 90
Study 1510000 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg body weight in 10 minutes)
Number of subjects: 90
Study 1510000 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg in 1 minute)
Number of subjects: 90
Study 1510000 — intervention group
Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 90
Study 1510000 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 90
Study 6355010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 108
Study 6355010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 108
Study 6355010 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 108
Study 6355010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 30711961 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 114
Study 30711961 — intervention group
Group type: COMPARATOR
Intervention: Minicholecystectomy (MC)
Number of subjects: 114
Study 29776916 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR light therapy (940 nm) to acupoints in the legs and feet, 12 sessions during hemodialysis three times a week
Number of subjects: 60
Study 29776916 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study 29776916 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR light therapy (940 nm) to acupoints in the legs and feet
Number of subjects: 60
Study 26462038 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed pin configuration
Number of subjects: 60
Study 26462038 — intervention group
Group type: COMPARATOR
Intervention: Lateral pin configuration
Number of subjects: 60
Study 25640007 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day SCSE for 14 days
Number of subjects: 10
Study 25640007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24285458 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized physiotherapy methods (6 additional massage treatments, 30 minutes each, over a few days)
Number of subjects: 30
Study 24285458 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pharmacological treatment and basic physiotherapy)
Number of subjects: 30
Study 21034249 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage treatment (3×10^9 plaque forming units) administered via oral gavage at 24 and 48 hours
Number of subjects: 48
Study 21034249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phage treatment)
Number of subjects: 48
Study 21034249 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage treatment
Number of subjects: 48
Study 18298241 — intervention group
Group type: EXPERIMENTAL
Intervention: Live interactive group-specific normative feedback intervention
Number of subjects: 1162
Study 18298241 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 1162
Study 16572330 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% water-soluble reduced chitosan (5.0 g/l)
Number of subjects: 12
Study 16572330 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 12
Study 16572330 — intervention group
Group type: COMPARATOR
Intervention: 0.1% chlorhexidine solution
Number of subjects: 12
Study 12573306 — intervention group
Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 49
Study 12573306 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (EV) 2 mg
Number of subjects: 49
Study 12573306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8682988 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent potassium nitrate: 0.243 percent sodium fluoride dentifrice
Number of subjects: 0
Study 8682988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically proven, commercially available desensitizing dentifrices
Number of subjects: 0